A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)

Table 2 Immunohistological assessment of metastases in antibody-treated and non-treated (control) HTM and TM

SK-BR-3 transplanted HTM and TM were immunohistologically stained using anti-HER2 antibodies in the lung, liver, and brain. HTM were analyzed in the age of 9 weeks (start of therapy) and in the age of ~ 21 weeks (end of therapy/experiment). The number of animals with detectable HER2-positive metastasis of the total number of animals (n/n) is indicated. Statistical differences were calculated using the two-sided Fisher’s exact test and significant differences are marked in italics

ISSN: 1479-5876